Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design.

X-ray crystal structures at 2.9 Å resolution are reported for two complexes of catechol diethers with HIV-1 reverse transcriptase. The results help elucidate the structural origins of the extreme antiviral activity of the compounds. The possibility of halogen bonding between the inhibitors and Pro95 is addressed. Structural analysis reveals key interactions with conserved residues P95 and W229 of importance for design of inhibitors with high potency and favorable resistance profiles.

[1]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[2]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[3]  François Diederich,et al.  Systematic investigation of halogen bonding in protein-ligand interactions. , 2011, Angewandte Chemie.

[4]  Joseph D. Bauman,et al.  Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design , 2008, Nucleic acids research.

[5]  William L Jorgensen,et al.  Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. , 2011, Journal of medicinal chemistry.

[6]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[7]  N. Sluis-Cremer,et al.  Probing nonnucleoside inhibitor‐induced active‐site distortion in HIV‐1 reverse transcriptase by transient kinetic analyses , 2007, Protein science : a publication of the Protein Society.

[8]  Robert A. Domaoal,et al.  Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase. , 2012, Bioorganic & medicinal chemistry letters.

[9]  F. Ceccherini‐Silberstein,et al.  High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations , 2005, Journal of Virology.

[10]  R. Esnouf,et al.  Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. , 2000, Molecular pharmacology.

[11]  T. Steitz,et al.  Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Timothy Clark,et al.  Halogen bonding: an electrostatically-driven highly directional noncovalent interaction. , 2010, Physical chemistry chemical physics : PCCP.

[13]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[14]  Xianfeng Lin,et al.  Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. , 2010, Bioorganic & medicinal chemistry letters.

[15]  Pierangelo Metrangolo,et al.  Fluorine-Centered Halogen Bonding: A Factor in Recognition Phenomena and Reactivity , 2011 .

[16]  Christophe Meyer,et al.  Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. , 2005, Journal of medicinal chemistry.

[17]  D I Stuart,et al.  Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. , 1998, Biochemistry.

[18]  Patric Schyman,et al.  Treatment of Halogen Bonding in the OPLS-AA Force Field; Application to Potent Anti-HIV Agents. , 2012, Journal of chemical theory and computation.